CDK4 and neoplasm: Although treatment with CDK4/6 inhibitors alone can delay tumor growth, some evidence demonstrated that CDK4/6 inhibitors induce nongenetic changes resulting in therapeutic failure, such as activation of the PI3K–AKT–mTOR signaling pathway, activation of cyclin E-CDK2 pathway and occurrence of autophagy [16,17].